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Tissue Engineering Research Involves Several Avenues of Study
(Continued from page 1)
organ-specific or site-specific cells from
the patient. Theoretically, cells from a
small tissue biopsy, expanded in cell
culture, can be combined with biodegradable scaffolds and other factors to
yield a nearly unlimited amount of
certain tissues. Charles Butler, M.D.,
an associate professor in the Department
of Plastic Surgery and director of M. D.
Anderson’s Plastic Surgery Clinic,
envisions profound potential for tissue
engineering: new skin, bone, fat, and
cartilage, even new organs to replace
diseased ones. “Consider a firefighter
who sustains deep burns over large areas
of his body. The physicians treating him
could rapidly generate new skin for any
part of his body, derived from his own
donated cells. His skin cells could have
been collected from a small biopsy when
he signed on his job and banked for this
purpose,” said Dr. Butler, whose research
interest focuses largely on engineering
skin and other epithelial tissues.
In fact, it is nearly impossible to
exaggerate the potential of tissue
engineering technology. Likewise, it
is difficult to overstate the complexity
of producing clinically viable engineered tissue. To manipulate cells to
grow, develop in specialized ways, and
sustain their life without becoming
abnormal, tissue engineers must come
to understand things about cells that
are not now known. This will not
be the work of one scientist, nor the
work of one branch of science, but the
collaboration of many—life scientists,
bioengineers, and clinicians.
Many and varied research questions
must therefore be addressed, one of the
most important and fundamental being
how to establish a blood supply. The
complexity of this task depends on the
tissue to be manufactured. “Cartilage,
for example, is relatively avascular and
has very low metabolic requirements.
Epidermis can survive by nutrient
diffusion. But all other tissues require
a patent microvascular system, so the
study of angiogenesis on a cellular and
molecular level is one of the crucial
aspects of this research,” said Charles
Patrick, Jr., Ph.D., an associate professor
and director of research in the Department of Plastic Surgery. Dr. Patrick,
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Tissue Engineering: How It’s Done

T

he basic strategy for developing engineered tissues is to
create a structure and an
environment where cells—ideally
autologous cells harvested from a
small biopsy—can grow and differentiate to become the needed tissue.
The main components of such a
system are the cells themselves (inside
a specially designed microenvironment), a scaffold, and an incubation
environment, or bioreactor.
The microenvironment includes
the tissue cells and other ingredients
such as support cells, growth factors,
genetic factors, and other components
that will help regulate and control
cell growth. It also may contain drugs
such as antibiotics, as well as other
chemical agents that can influence
such cell behaviors as proliferation,
differentiation, and migration.
Synthetic systems that can control
the release and delivery of drugs and
other chemical factors may also be
part of the design.
The scaffold may be made of
natural, synthetic, or hybrid material.
Synthetic polymers are often used
since they can be chemically manipu-

whose research focuses on the synthesis
and composition of biomaterials needed
for the scaffold and the microenvironment of engineered tissue, coupled
with cell biology and clinical science,
collaborates extensively with chemical
engineering colleagues at Rice University and The University of Texas, as
well as with his Plastic Surgery colleagues.
While scientists are learning a great
deal about angiogenesis in tumors, little
is known about neovascularization—
the formation of capillary networks—
in engineered tissue. One of the challenges is that vessels at the capillary
level are so small that they are difficult
to see, even with sophisticated imaging
modalities. This is one area of interest
for Greg Reece, M.D., a professor in the
Department of Plastic Surgery whose
specialty in microvascular surgery has

lated to achieve the optimum shape,
configuration, porosity, biomechanics,
and surface design. Some scaffolds are
woven or nonwoven meshes, some
resemble sponges or foams, and others
are hydrogels that can be injected to
repair internal defects. In some cases,
the scaffold is a permanent part of
the tissue construct, but scaffolds
can be chemically programmed to
biodegrade and disappear as the
tissue grows.
The bioreactor is the environment
used to incubate the growing tissue.
Small volumes of simple tissues can
be grown for short periods of time in
fairly conventional laboratory apparatuses: a petri dish and incubator, for
example. But more sophisticated
environments will be necessary for
real clinical applications of this
technology, as the interactions among
the scaffold, its seeded material, and
the bioreactor can be manipulated
to maximize cell viability and stability.
Mechanically active, rotating bioreactors are one possible model; in
another, the scaffold and microenvironment are implanted, and the patient
becomes the bioreactor. ●
led him to try to measure the number
and morphology of these tiny vessels.
Dr. Reece and his colleagues in the
Department of Plastic Surgery have
produced what may be the first threedimensional images of capillaries
growing across the interface between
a skin graft and the wound bed of the
recipient site. Dr. Reece acquires the
skin grafts from a small animal model,
and histotechnologist Carol Johnston
serially sections each specimen (the
graft and underlying wound bed) on a
cryostat. Xuemei Wu, M.D., a senior
research assistant, then stains the
sections with an antibody against the
lining of the blood vessels. A computeroperated microscope produces serial
images of each histologic section, which
are then tiled together to make a single,
digitized mosaic image, similar to a

satellite photograph. Each tiled image is
then assigned two colors: red for blood
vessels and black for everything else.
Using a computer program designed
by Dr. Patrick and Eric Brey, a Rice
University graduate student, the tiled
images are realigned into a single threedimensional image that allows the
researchers to quantify the blood vessels
and determine their histomorphology.
“This is very difficult to do, however,
because it relies on the expertise of the
histotechnologist in serial sectioning and
requires the computer to align the serial
tiled images with an accuracy of a quarter
of a micron,” said Dr. Reece. In addition,
he said, the technique is a one-time
view of blood vessel growth in the tissue
sample, not a way to observe what is
happening over time within the tissue.
But it is an important first step, offering
visual evidence of blood vessel growth
into the natural fibrin gel that bridges
the interface between the graft and the
wound. But, said Dr. Reece, “There is
much to be discovered before we are
able to learn how to distribute a new
microvasculature over a large tissue
construct in the same way Mother
Nature does in a conventional tissue
graft.”
In addition to providing adequate
vascularization for engineered tissue,
researchers must overcome the challenge of creating and maintaining a
three-dimensional tissue construct that
is large enough to be clinically relevant.
“We must also ensure that the induced
tissue reaches equilibrium and does not
become malignant tissue—as growth
factors and other factors involved in
angiogenesis and adipogenesis are also
intimately involved in tumor formation,” said Dr. Beahm, whose research
focuses on engineering adipose tissue for
soft tissue repairs. Furthermore, growth
factors used for tissue induction are
species specific, so the path from small
to large animal models is not direct, and
there is much to be learned. “Translational research and long-term studies in
large animals are critical,” Dr. Beahm
said. “This is a series of small projects,
but it will be extraordinary indeed when
we are able to create three-dimensional,
vascularized fat constructs.”

Histologic cross sections of keratinocyte-seeded
collagen-glycosaminoglycan (CG) matrices
show the simultaneous formation of dermal
and epidermal tissue. At one week, most of
the CG matrix remains undegraded, and
cellular infiltration and neovascularization
are located mostly in the lower half of the graft.
At two weeks, however, the epidermis and
neodermis have changed dramatically.
The CG matrix is now completely infiltrated
with cells and blood vessels, and a confluent,
multilayered, stratified epidermis is seen.
In the neodermis, keratinocyte cysts have
formed from the proliferation of keratinocytes
that were unable to completely traverse the
matrix to the silicone-matrix junction during
centrifugation. At three weeks, the CG
matrix has been completely replaced with
vascularized neodermis, and the keratinocyte
cysts are completely absent, having unidirectionally migrated through the developing
neodermis to fuse with the epidermis and
help form it.

Skin is critical for oncologic
reconstruction because cancer treatment frequently requires the resection
of skin and subcutaneous tissue, which
are usually replaced with skin grafts or
tissue flaps. With his colleagues at
Harvard University and Massachusetts
Institute of Technology, Dr. Butler has
developed a tissue-engineered skin
substitute that simultaneously regenerates both dermis and epidermis and
can be grafted during a single procedure. Production of this skin substitute
involves impregnating a specialized,
biodegradable synthetic construct with
host skin cells derived from a small
skin sample. Because tissue properties
such as thickness, color, elasticity, and
the presence of hair follicles and glands
vary depending on where the tissue is
located, the goal is to regenerate tissues
that closely match the recipient site.
Dr. Butler and his colleagues are
studying the skin substitute in animal
models and hope to begin clinical trials
in patients soon.
Protocols are also under way to study
the prefabrication and prelamination of
specialized tissues such as those that
make up the nipple and areola of the
breast, oral mucosa, lips, and vaginal
mucosa. Dr. Butler and his colleagues
have been able to regenerate oral

mucosa with a technique using cells
from the oral cavity. He is also working
to develop more sophisticated tissue
flaps that contain more than one type
of site-specific tissue. These “custom”
tissue flaps will be used to repair complex composite defects that involve
several types of tissue.
Repairing defects in bone involves
challenges similar to those encountered
in soft tissue repair: the shortage of
harvest sites, the need for a blood
supply, and the difficulty of re-creating
special functions. In addition, bone has
greater structural duties and must be
prefabricated in an exact shape and size.
“My research in this area focuses on
creating a large animal model to use as
a platform to understand and assess the
effectiveness of different tissue engineering methods,” said Michael J. Miller,
M.D., a professor in the Department of
Plastic Surgery. “We need to work with
bones that are large enough to require a
blood supply similar to that of a human
femur.” In a recent protocol using tissue
engineering principles in large animal
models, Dr. Miller and his colleagues
created a mandible that was engineered
in synthetic scaffolds using osteogenic
cell populations and bone induction
factors and attached it to the blood
(Continued on page 4)
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Researchers Design a Unique St
Radiosurgery System to Treat Pa
by Dawn Chalaire

W

ith the development of a unique stereotactic radiotherapy and radiosurgery (SRT/SRS) system that
precisely delivers high doses of radiation to paraspinal tumors, researchers at The University
of Texas M. D. Anderson Cancer Center are taking the first
steps toward expanding the use of stereotactic radiation delivery
beyond the treatment of tumors in the brain.

Dr. Michael J. Miller, a professor in the
Department of Plastic Surgery, is developing
engineered bone to replace skeletal defects.
supply of the periosteum. This technique may soon be used for the first time
in a human—a young patient who lost
all of the bones of her nose, palate, and
the base of her skull to chondrosarcoma.
In yet another avenue of tissue
engineering research, Dr. Miller, in
collaboration with Dr. Patrick and other
colleagues at the University of Houston
and The University of Texas, is working
with computer simulation models. In a
current protocol, the researchers are
creating computer simulations of the
breast that will characterize the defect to
be repaired using sophisticated measurements and modeling of the size and
proportion of the tissue and its biomechanical properties. The simulations
will also take into account density and
elasticity, which govern how the tissue
moves and how it is affected by gravity.
Eventually, such a simulation will
characterize the three-dimensional
aspects of a defect and generate a
blueprint for building the scaffold, as
well as a recipe for the tissue microenvironment. ●
FOR MORE INFORMATION, contact the
Department of Plastic Surgery at
(713) 794-1247.
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“It’s very challenging to do stereotactic treatment outside of the brain,”
said Eric L. Chang, M.D., an assistant
professor in the Department of Radiation Oncology and radiation oncologist
in charge of the new stereotactic spine
radiotherapy program at M. D. Anderson, a collaborative effort between the
Division of Radiation Oncology and
the Department of Neurosurgery. “For
intracranial radiosurgery, the skull can
be fixated in space with neurosurgical
screws. Immobilization, which is crucial
for any stereotactic treatment, is a tour
de force for lesions outside the brain
because the body is made up of soft
tissues that are difficult to immobilize
and can move in relation to one
another.”
Dr. Chang is the principal investigator
leading a phase I/II clinical trial to
evaluate the safety and feasibility of a
painless, noninvasive spinal SRT/SRS
system in patients with one or two
paraspinal metastases. He and coinvestigators Almon Shiu, Ph.D., an
associate professor in the Department
of Radiation Physics, and Laurence
Rhines, M.D., an assistant professor in
the Department of Neurosurgery, also are
gathering evidence to determine whether
the treatment relieves or prevents pain
and other symptoms associated with
spinal tumors, including neurologic
dysfunction, pathologic fractures, and
spinal instability.
“Unfortunately, it’s a common
situation in many cancers, especially
breast, lung, and prostate cancers, that
metastatic tumors affect the vertebrae.
When the tumors progress, they invade
the spinal cord and cause paraplegia, a

devastating neurological condition.
We would like to treat the spine but
without the side effects, without giving
a significant dose [of radiation] to the
spinal cord. So precision is very important in the treatment of these patients,”
said Moshe Maor, M.D., a professor in
the Department of Radiation Oncology.
Dr. Maor knows a great deal about
the precise delivery of radiation. A
decade ago, he and Dr. Shiu began
using stereotactic radiosurgery (SRS)
to treat patients with brain tumors. SRS
overcomes the radioresistance of many
metastatic brain tumors by delivering
a high dose of radiation in a single
fraction.
Several hundred patients have
undergone SRS treatment for brain
tumors, and the results are excellent.
The control rate in all brain metastases
is at least twice that of conventional
radiation therapy, and in radioresistant
metastases, such as those from renal cell
carcinoma, sarcoma, and melanoma, the
control rate is 65% to 80% higher than
with conventional radiation therapy.
This success has led researchers at M. D.
Anderson and elsewhere to attempt to
expand the applications of SRT/SRS
to critical areas outside the brain.
The spine, with its propensity for
developing metastatic disease and its
proximity to the spinal cord, was a
logical choice for an initial attempt at
extracranial SRT/SRS. But investigators
first had to overcome the problem of
movement. In SRS to the brain, the
stereotactic coordinates of the treatment isocenter can be transferred with
confidence to a metal head frame that
will not allow the patient to move, but

tereotactic Radiotherapy and
atients with Paraspinal Metastases

Dr. Eric L. Chang, an assistant professor in the Department of Radiation Oncology,
stands by as Lisa Ciuray, a radiation therapist, moves
into position for
computed tomographic imaging during a “dry run” to test the newly developed stereotactic
radiotherapy and radiosurgery (SRT/SRS) system to treat paraspinal metastases.
is encased in plastic sheeting to immobilize her during the procedure.
the treatment target in spinal tumors
must be transferred in a different way
and then verified before treatment.
This verification is made possible by
a unique combination of immobilization
techniques and the use of a recently
installed combined computed tomography (CT)-linear accelerator unit, the
acquisition of which was spearheaded by
James D. Cox, M.D., professor and head
of the Division of Radiation Oncology
(please see related article in the December 2002 issue of OncoLog). With the
combined CT-linear accelerator, a single
treatment table rotates 180 degrees and
a CT scanner moves on rails, making it
possible to take CT images and deliver
radiation therapy while the patient
remains in the same treatment position.
Dr. Shiu, who has overseen the
development of SRT/SRS at M. D.
Anderson from the very beginning,
modified a commercial body immobilization system to the new spinal SRT/

SRS technique. While patients lie
supine on a Styrofoam cushion, air is
extracted from the cushion to mold it
to the underside of the body. (The
cushion retains the patient’s impression
so that the position can be duplicated
throughout subsequent imaging and
treatment.) A plastic sheet is placed
over the patient and carefully adhered
to the sides of the cushion until it is
airtight. Then a vacuum hose attached
to the sheet removes all of the air inside
until the plastic clings tightly to the
patient’s body, minimizing vertebral
body motion associated with breathing
during CT imaging and treatment
delivery. A three-sided localization
frame attaches to the treatment table,
over the target area, and rods on the
edges of each of the frame’s three panels
serve as reference points in the stereotactic coordinate system.
“But we are still missing the rigid link
between the patient’s anatomy and the

stereotactic coordinate system,” said
Dr. Shiu. “By fusing the daily pretreatment CT images with the planning
CT images, we can determine how the
patient, especially the vertebral body
target, has been shifted, rotated, or both
with respect to the setup position of
simulation.”
After dosimetry calculations are
completed, planning CT scans of the
treatment area are taken and used to
generate a pair of digital reconstructive
radiographs (DRRs) showing the
treatment isocenter and surrounding
patient anatomy. Later, on the treatment day, CT images of the patient are
taken prior to treatment. These daily
CT images are fused with the planning
CT images to see if the patient has
shifted or rotated. Based on this information, a pair of daily DRRs with the
updated isocenter are generated. These
daily DRRs are compared with the
planning DRRs and, if necessary, fine
adjustments are made. Then, the
corrected isocenter is marked on the
positioning frame to align the target
isocenter with the linear accelerator’s
radiation isocenter using lasers. Prior
to the delivery of radiation, orthogonal
portal images are acquired and compared with the planning DRRs for a
final verification. Immediately after
treatment, another CT is taken and
compared with the daily CT to see
if any movement occurred during
treatment.
“The radiation treatment plan is
developed from a planning CT image
taken on the simulation day. On the day
of treatment, the patient’s body could
have moved from the simulated treatment position. A near-real-time CT
image taken right before treatment is
used for comparison with the planning
CT so that any discrepancy in patient
positioning can be corrected immediately,” said Dr. Chang.
The precise delivery of SRT/SRS
makes it possible to treat tumors with
higher doses of radiation without
damaging adjacent tissues. The current
study calls for five fractions, each
(Continued on page 6)
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(Continued from page 5)
consisting of a 6-Gy dose. Giving higher
doses of radiation per fraction serves two
purposes: it allows for fewer fractions to
achieve the total dose, thus limiting the
number of times the complicated SRT/
SRS procedure has to be performed, and
it may overcome radioresistance in some
spinal tumors.
“Radiation therapy doses that we’ve
been able to use with conventional
radiation therapy have been limited by
what the spinal cord can tolerate,” said
Dr. Rhines. “As you can imagine, there
are certain types of tumors whose lethal
dose is less than what the spinal cord
can tolerate. And so if you give up to
the tolerated dose, those tumors are
treated effectively. But there are a whole
host of other tumors—renal cell carcinoma, sarcomas, etc.—that if you don’t
give anything more than what the
spinal cord can tolerate, the tumors are
not effectively treated. So what stereotactic radiosurgery allows us to do is
plan a radiation treatment that delivers
much more radiation to the tumor
and spares the spinal cord.”
Typically, Dr. Chang said, the risk
of paralysis precludes a second course
of conventional radiation therapy to the
spine. Because SRT/SRS can spare the
spinal cord from a clinically significant
dose of radiation, however, the current
study is open to patients who have
previously had radiation therapy to
the spine.
“Many patients who have been
previously irradiated develop recurrent
disease and at that point, their only
option is a major surgery that involves
surgical risks, recovery time, and rehabilitation,” said Dr. Chang. “Of course, there
are situations when surgery is the best
and only option, but there are also other
cases where the surgeons prefer not to
operate and wish they had a noninvasive
alternative. The new stereotactic spine
radiotherapy program is being developed
to help meet that need.”
Historically, Dr. Rhines said, surgeons at M. D. Anderson have treated
spinal metastases very aggressively and
have had good success with surgical
techniques to restore function and
reduce pain. “But it’s still a lot for the
patients to go through,” he said. “If the
6
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Dr. Almon Shiu, an
associate professor in the
Department of Radiation
Physics, prepares a patient
for spinal stereotactic radiotherapy and radiosurgery
(SRT/SRS) in the combined
computed tomographylinear accelerator treatment
room (top photo).
At right, Dr. Laurence
Rhines, an assistant
professor in the Department
of Neurosurgery, discusses
radiographic images with
patient
.
same thing could be done with a
noninvasive treatment that I can do
with a scalpel, I think that’s a tremendous advantage for the patient.”
In addition, many patients with
spinal metastases are not eligible for
surgery because they are too sick to
undergo anesthesia, their overall disease
is too advanced, or the tumor is located
in an area that makes its removal
unfeasible. Chemotherapy is sometimes
used to treat spinal metastases, but it
is not always effective, and systemic
therapy is often avoided in patients
with limited disease.
Dr. Rhines, who also directs the Spine
Program in the Department of Neurosurgery, uses his experience to help select
patients for the spinal SRT/SRS protocol. “Because of the volume of patients
we see, we’re able to make some predic-

tions about how a patient’s spine tumor
might behave, and this helps guide our
treatment. Patients with spinal fractures,
cord compression, or evidence of instability may be better treated with surgery.
Stereotactic radiotherapy can then be
used postoperatively or at the time of
recurrence,” he said.
The investigators hope to accrue 90
patients into the ongoing clinical trial.
If the SRT/SRS system is shown to be
safe and effective, the next step will be
to investigate even shorter courses of
SRT/SRS to the spine involving three
and, ultimately, a single fraction of
radiation. ●
To obtain an informational videotape or to
refer patients for the CT-guided stereotactic
spine radiotherapy protocol, contact Leni
Mathews, R.N., at (713) 792-3332.

